Who we are
Created in partnership with Parkinson’s UK, one of the world’s largest charity funders of Parkinson’s research, the Critical Path for Parkinson’s Consortium (CPP) was launched on October 14, 2015. This is a global collaboration that promises to pave the path to new treatments for Parkinson’s. By facilitating collaboration among scientists from the bio-pharmaceutical industry, academic institutions, government agencies, and patient-advocacy associations, CPP fosters consensus and data-driven research to increase efficiency, safety, and speed in developing new therapies.
Traditionally, Parkinson’s has been viewed as a disorder in which individuals don’t have enough of a chemical called dopamine because specific nerve cells inside their brain have died. Current research indicates that the processes that lead to dopamine deficit start much earlier (decades) making it a pressing need to increase the understanding of Parkinson’s progression.
It is CPP’s mission to serve as the main international vehicle to develop new, regulatory-endorsed drug development tools based on the most current scientific insights into early Parkinson’s, by combining detailed patient data, expertise in clinical trials from companies and academia, and the unique neutral facilitator role of non-profit organizations.
“It’s our goal that the partnership with the Critical Path Institute will improve the clinical trial process and deliver new and better treatments, faster, to the people who urgently need them,” says Parkinson’s UK Chief Executive Steve Ford.
How we do it
CPP has collected and standardized patient-level data from PD patients around the world to develop a global integrated unified database. CPP aims to achieve global regulatory endorsement of novel translational biomarkers and drug disease trial models for use in clinical drug development trials. CPP focuses on early stages of PD, a time that offers the best chance for delaying disease progression. Early intervention is a priority need as expressed by patients.